Boston

Biotech

How swallowing a star might keep you from missing a dose of medicine

By Jonathan Saltzman — Boston Globe

Open Heart Surgery

Health

‘Donation after cardiac death’: New heart transplant method being tested for the first time in the U.S.

By Shraddha Chakradhar

advertisement

STAT SPOTLIGHT

Biotech

Startup Spotlight: With a different method for gene therapy, Generation Bio eyes an IPO

By Kate Sheridan

advertisement

Biotech

Agios CEO forecasts ‘line of sight’ to more approved drugs and profits

By Adam Feuerstein

Alexis Borisy portrait

Biotech

A ‘radical proposition’: A health care veteran tries to upend the system and bring drug prices down

By Matthew Herper

DNA strand repair

Biotech

Blueprint gains approval for its first drug, a treatment for a rare gastrointestinal cancer

By Jonathan Saltzman — Boston Globe

Sound wave

Health Tech

Pear Therapeutics licenses voice biomarkers for dementia and psychiatric disorders

advertisement

Knee replacement

Biotech

Anika Therapeutics acquires two companies for their joint-replacement products

By Jonathan Saltzman — Boston Globe

advertisement

Adam's Take

Biotech 2020 preview: Takeover targets, notable drug launches, and genome editing readouts

By Adam Feuerstein

Scorecard

Biotech

The biotech scorecard for the first quarter: 14 stock-moving events to watch

By Adam Feuerstein

Jary Larsen

Biotech

An uncommon form of dementia hits at a younger age. Drug makers are searching for a treatment

By Jonathan Saltzman — Boston Globe

Robert Moir

In the Lab

Unorthodox Alzheimer’s researcher Robert Moir dies at age 58

By Sharon Begley

CRISPR-edited pigs

In the Lab

Creating Pig3.0, the world’s most CRISPR’d animal, raises hopes of transplantable organs

By Sharon Begley

Good/Bad CEO 2017

Adam's Take

Maraganore victorious in best biopharma CEO tally; Vounatsos tops worst list

By Adam Feuerstein

ASH19 sickle cell disease blood sample

Biotech

In a shift toward venture capital fundraising, FORMA Therapeutics brings in $100 million

By Kate Sheridan

ASH19 Gene Therapy Sickle Cell

Biotech

Research pact between Syros Pharma, Global Blood seeks new drugs to treat sickle cell disease

By Adam Feuerstein

Bone marrow transplant

Biotech

Cutting-edge therapies promise one-time cures, but not without risk. Can biotech make them safer?

By Adam Feuerstein

Genome

Biotech

Startup targeting DNA repeats in Huntington’s and other diseases debuts with $59 million

By Jonathan Saltzman — Boston Globe

Alnylam RNAi

Biotech

Alnylam chalks up another win with phase 3 trial of a rare-disease drug

By Kate Sheridan

Excellent

In the Lab

Female researchers are less likely than men to frame their work with positive words, study finds

By Elizabeth Cooney

RNA illustration

Biotech

Wave Life Sciences crashes on negative outcome of Duchenne muscular dystrophy study

By Adam Feuerstein

Cambridge: Sarepta

Biotech

FDA changes course on Sarepta’s once-rejected muscular dystrophy drug

By Damian Garde

Surgery

Health

Surgeons test-drive the amputation of the future with a mail-order limb, rerouted nerve, and prosthetic hand that grips like the real thing

Something ventured illo

Biotech

Something Ventured: Akrevia Therapeutics and three other startups got venture funding a year ago. Did it help them do what they said it would?

By Kate Sheridan

Vivitrol Opioids

Politics

FDA blasts Alkermes for underselling the risks of opioid addiction drug Vivitrol

Omega Funds Entrance

Biotech

In its largest fundraising effort to date, Omega Funds pulls in over $400 million

By Kate Sheridan

Kendall - Longfellow bridge

Biotech

In tight Massachusetts job market, it’s relo for biotech and remote for tech hires

By Scott Kirsner — Boston Globe

Colorful DNA molecule

Biotech

Merck and Sanofi buy smaller cancer drug firms at big premiums, fueling investor excitement

By Matthew Herper

Biotech

New data show Bluebird, Bristol CAR-T drug could be pioneering myeloma therapy. Competitors may be close behind

By Adam Feuerstein and Damian Garde